Omarigliptin: A new kind of long acting DPP-4 inhibitor

VernacularTitle:奥格列汀:一种新的长效二肽基肽酶-4抑制剂
Author: Hongnan CHEN ; Ying DENG ; Xiujuan GUO ; Guodong HUA
Keywords: Omarigliptin; DPP-4 inhibitor; oral hypoglycemic agents
From: Drug Evaluation Research 2017;40(1):133-137
CountryChina
Language:Chinese
Abstract: Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day,which brings inconvenience to patients.Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor.The drug is developed by the Merck Co,mainly for the treatment of type two diabetes.The drug only need to be taken once a week,so as to improve the patient's compliance and adherence,thereby improving the therapeutic effect.This article introduces the information of omarigliptin from the aspects of synthesis,pharmacology,pharmacokinetics,and clinical research,which provides valuable information for pharmaceutical workers.